Yasser Ged

1.8k total citations
59 papers, 549 citations indexed

About

Yasser Ged is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Oncology. According to data from OpenAlex, Yasser Ged has authored 59 papers receiving a total of 549 indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Pulmonary and Respiratory Medicine, 27 papers in Cancer Research and 22 papers in Oncology. Recurrent topics in Yasser Ged's work include Renal cell carcinoma treatment (45 papers), Cancer Genomics and Diagnostics (23 papers) and Renal and related cancers (18 papers). Yasser Ged is often cited by papers focused on Renal cell carcinoma treatment (45 papers), Cancer Genomics and Diagnostics (23 papers) and Renal and related cancers (18 papers). Yasser Ged collaborates with scholars based in United States, Austria and Ireland. Yasser Ged's co-authors include Martin H. Voss, Robert J. Motzer, A. Ari Hakimi, Sujata Patil, Chung‐Han Lee, Timothy A. Chan, Andrea Knežević, Darren R. Feldman, Paul Russo and Maria I. Carlo and has published in prestigious journals such as JAMA, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Yasser Ged

53 papers receiving 542 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yasser Ged United States 12 361 244 212 169 87 59 549
J.B. Auliac France 15 604 1.7× 121 0.5× 433 2.0× 161 1.0× 79 0.9× 64 741
Kumaran Mudaliar United States 11 335 0.9× 168 0.7× 117 0.6× 110 0.7× 82 0.9× 37 531
Kyrillus S. Shohdy Egypt 12 213 0.6× 88 0.4× 197 0.9× 114 0.7× 59 0.7× 39 440
Joanna Huszno Poland 11 146 0.4× 131 0.5× 193 0.9× 102 0.6× 61 0.7× 37 425
Cinzia Baldessari Italy 13 207 0.6× 102 0.4× 292 1.4× 50 0.3× 107 1.2× 43 464
Yuko Oya Japan 14 615 1.7× 134 0.5× 530 2.5× 142 0.8× 70 0.8× 48 777
J.M. Sánchez-Torres Spain 13 428 1.2× 150 0.6× 614 2.9× 104 0.6× 43 0.5× 21 772
Justin S. Gundara Australia 13 98 0.3× 316 1.3× 141 0.7× 328 1.9× 221 2.5× 52 749
Valentina Tateo Italy 10 150 0.4× 114 0.5× 205 1.0× 96 0.6× 106 1.2× 36 437
Eduardo Cervera Mexico 6 86 0.2× 237 1.0× 189 0.9× 109 0.6× 72 0.8× 12 505

Countries citing papers authored by Yasser Ged

Since Specialization
Citations

This map shows the geographic impact of Yasser Ged's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yasser Ged with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yasser Ged more than expected).

Fields of papers citing papers by Yasser Ged

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yasser Ged. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yasser Ged. The network helps show where Yasser Ged may publish in the future.

Co-authorship network of co-authors of Yasser Ged

This figure shows the co-authorship network connecting the top 25 collaborators of Yasser Ged. A scholar is included among the top collaborators of Yasser Ged based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yasser Ged. Yasser Ged is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Elias, Roy, Thomas R. Nirschl, Michael E. Rezaee, et al.. (2025). Clear-Cell Renal Cell Carcinoma Molecular Subtypes Differ by African and European Genetic Similarity. Cancer Research Communications. 5(5). 743–755. 1 indexed citations
2.
Ged, Yasser, Luis Contreras, Roy Elias, et al.. (2025). Multi-institutional Analysis of Immune-Oncology Combination Therapy for Metastatic MiT Family Translocation Renal Cell Carcinoma. Journal of Immunotherapy. 48(3). 113–117. 1 indexed citations
3.
Singh, Rajiv K., Zirui Jiang, Vanessa F. Merino, et al.. (2024). Performance of PSMA-targeted radiotheranostics in an experimental model of renal cell carcinoma. Frontiers in Oncology. 14. 1432286–1432286.
4.
Dizman, Nazlı, Andrea Knežević, Reza Alaghehbandan, et al.. (2024). A multi-institution analysis of outcomes with first-line systemic therapy for 99 patients with metastatic chromophobe renal cell carcinoma.. Journal of Clinical Oncology. 42(16_suppl). 4512–4512. 3 indexed citations
5.
Yarchoan, Mark, John D. Powderly, Bruno R. Bastos, et al.. (2024). First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors. Cancer Research Communications. 4(4). 1100–1110. 11 indexed citations
6.
Singla, Nirmish, Thomas R. Nirschl, Aleksandar Obradović, et al.. (2024). Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma. Scientific Reports. 14(1). 1458–1458. 4 indexed citations
7.
Rezaee, Michael E., Maximilian Pallauf, Sean A. Fletcher, et al.. (2024). Prognostic significance of pT3a staging subclassifications in renal cell carcinoma: Not all pT3a are equal. Urologic Oncology Seminars and Original Investigations. 42(4). 119.e23–119.e29. 2 indexed citations
8.
9.
Alam, Ridwan, Michael E. Rezaee, Maximilian Pallauf, et al.. (2023). Socioeconomic determinants of racial disparities in survival outcomes among patients with renal cell carcinoma. Urologic Oncology Seminars and Original Investigations. 41(11). 460.e1–460.e9. 3 indexed citations
10.
Deutsch, Julie S., Evan J. Lipson, Ludmila Danilova, et al.. (2023). Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma. Cell Reports Medicine. 4(2). 100947–100947. 18 indexed citations
11.
Pallauf, Maximilian, Yasser Ged, & Nirmish Singla. (2023). Molecular differences in renal cell carcinoma between males and females. World Journal of Urology. 41(7). 1727–1739. 6 indexed citations
12.
Ged, Yasser, Alejandro Sánchez, Sujata Patil, et al.. (2022). Associations between Pretreatment Body Composition Features and Clinical Outcomes among Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Blockade. Clinical Cancer Research. 28(23). 5180–5189. 20 indexed citations
13.
Ged, Yasser, Mark C. Markowski, Nirmish Singla, & Steven P. Rowe. (2022). The shifting treatment paradigm of metastatic renal cell carcinoma. Nature Reviews Urology. 19(11). 631–632. 7 indexed citations
14.
Avery, Robin K., et al.. (2022). Case Report: New Onset Lymphadenopathy After Immune Checkpoint Inhibitor Therapy Presents a Clinicopathological and Radiological Challenge. Frontiers in Oncology. 12. 876797–876797. 2 indexed citations
15.
Esfandiary, Tina, Joseph Cheaib, Sunil Patel, et al.. (2022). Characterizing Tumor Thrombus Arising from Non–Clear Cell Renal Cell Carcinoma. European Urology Open Science. 43. 28–34. 7 indexed citations
16.
Alam, Ridwan, Hiten D. Patel, Zhuo T. Su, et al.. (2021). Self‐reported quality of life as a predictor of mortality in renal cell carcinoma. Cancer. 128(3). 479–486. 7 indexed citations
17.
18.
Feldman, Darren R., Yasser Ged, Chung‐Han Lee, et al.. (2020). Everolimus plus bevacizumab is an effective first‐line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial. Cancer. 126(24). 5247–5255. 27 indexed citations
19.
Hakimi, A. Ari, Kyrollis Attalla, Renzo G. DiNatale, et al.. (2020). A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response. Nature Communications. 11(1). 4168–4168. 44 indexed citations
20.
Sánchez, Alejandro, Helena Furberg, Fengshen Kuo, et al.. (2019). Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. The Lancet Oncology. 21(2). 283–293. 127 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by J.B. Auliac Breakdown of academic impact, for papers by Kumaran Mudaliar Breakdown of academic impact, for papers by Kyrillus S. Shohdy Breakdown of academic impact, for papers by Joanna Huszno Breakdown of academic impact, for papers by Cinzia Baldessari Breakdown of academic impact, for papers by Yuko Oya Breakdown of academic impact, for papers by J.M. Sánchez-Torres Breakdown of academic impact, for papers by Justin S. Gundara Breakdown of academic impact, for papers by Valentina Tateo Breakdown of academic impact, for papers by Eduardo Cervera
Rankless by CCL
2026